Bristol-Myers Squibb: Can BMY's CELMoD Program Advancements Strengthen Its Oncology Portfolio?
BMY's FDA filing for mezigdomide in relapsed or refractory multiple myeloma marks another step in advancing its protein degrader pipeline.
Read full article »
Bristol Myers Squibb is a New Jersey-based biopharmaceutical company that discovers, develops and commercializes medicines for patients with serious diseases.
Read more